Australia's largest medical research fund makes first investment in NZ business
Which early stage company is the lucky recipient of $8 million?
Australia's Medical Research Commercialisation Fund has plugged $8 million into early-stage pharmaceutical company Kea Therapeutics.
Kea, which is developing a new drug to relieve severe pain, was spun out of the Auckland Cancer Society Research Centre and the Faculty of Medical and Health
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Calida Smylie
Wed, 13 Dec 2017
Wed, 13 Dec 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Australia's largest medical research fund makes first investment in NZ business
72402